Press release
August 6, 2026
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
Tarsus Pharmaceuticals, Inc. (TARS)
Generated second quarter 2026 XDEMVY ® net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million Pending acquisition of Alkeus Pharmaceuticals to expand Tarsus’ retina pipeline with a Phase 3